The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TnFα therapy

Joint Bone Spine

Volumn 72, Issue 6, 2005, Pages 456-460

  Tubach, Florence ^a   Salmon Céron, Dominique ^b,c   Ravaud, Philippe ^a   Mariette, Xavier ^d,e  

^a BICHAT HOSPITAL   (France)

^b Internal Medicine Department ^*  (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Bicêtre Teaching Hospital   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Lymphoma; Rheumatoid arthritis; Safety; TNFalpha antagonists

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; ETANERCEPT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANAMNESIS; BACTERIAL INFECTION; CASE CONTROL STUDY; COHORT ANALYSIS; CONFERENCE PAPER; CROHN DISEASE; DISEASE SEVERITY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; FRANCE; HEALTH CENTER; HEALTH SERVICE; HUMAN; INFECTION PREVENTION; LEARNING; LYMPHOMA; MEDICAL SOCIETY; NONHUMAN; OBSERVATIONAL STUDY; OPPORTUNISTIC INFECTION; PATIENT MONITORING; PRESCRIPTION; PROFESSIONAL PRACTICE; PSORIASIS; REGISTER; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; RISK ASSESSMENT; SPONDYLOARTHROPATHY; TUBERCULOSIS; VALIDATION PROCESS;

BACTERIAL INFECTIONS; CASE-CONTROL STUDIES; FRANCE; HUMANS; LYMPHOMA; OPPORTUNISTIC INFECTIONS; REGISTRIES; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 29244482547     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2005.10.004     Document Type: Conference Paper

References (30)

1. E. Choy, and G. Panayi Cytokine pathways and joint inflammation in rheumatoid arthritis N. Engl. J. Med. 344 2001 907 916
2. S.J. van Deventer Tumor necrosis factor and Crohn's disease Gut 40 1997 443 448
3. T. Saxne, M.J. Palladino, D. Heinegard, N. Talal, and F. Wollheim Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum Arthritis Rheum. 31 1988 1041 1045
4. M. Rooney, H. Varsani, K. Martin, P.R. Lombard, J.M. Dayer, and P. Woo Tumour necrosis factor alpha and its soluble receptors in juvenile chronic arthritis Rheumatology (Oxford) 39 2000 432 438
5. M.M. Vazquez-Del, A. Garcia-Gonzalez, J.F. Munoz-Valle, T. Garcia-Iglesias, G. Martinez-Bonilla, and G. Bernard-Medina Interleukin 1beta (IL-1beta), IL-10, tumor necrosis factor-alpha, and cellular proliferation index in peripheral blood mononuclear cells in patients with ankylosing spondylitis J. Rheumatol. 29 2002 522 526
6. M. Kawaguchi, Y. Mitsuhashi, and S. Kondo Overexpression of tumour necrosis factor-alpha-converting enzyme in psoriasis Br. J. Dermatol. 152 2005 915 919
7. P.E. Lipsky, D.M. van der Heijde, E.W. St Clair, D.E. Furst, F.C. Breedveld, and J.R. Kalden Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor Necrosis factor trial in rheumatoid arthritis with Concomitant Therapy Study Group N. Engl. J. Med. 343 2000 1594 1602
8. F. Van den Bosch, E. Kruithof, M. De Vos, F. De Keyser, and H. Mielants Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms Lancet 356 2000 1821 1822
9. J.D. Gorman, K.E. Sack, and J.C. Davis Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha N. Engl. J. Med. 346 2002 1349 1356
10. C.L. Leonardi, J.L. Powers, R.T. Matheson, B.S. Goffe, R. Zitnik, and A. Wang Etanercept as monotherapy in patients with psoriasis N. Engl. J. Med. 349 2003 2014 2022
11. D. Schluter, and M. Deckert The divergent role of tumor necrosis factor receptors in infectious diseases Microbes Infect. 2 2000 1285 1292
12. P. Mastroeni, J.N. Skepper, and C.E. Hormaeche Effect of anti-tumor necrosis factor alpha antibodies on histopathology of primary Salmonella infections Infect. Immun. 63 1995 3674 3682
13. M.A. Gardam, E.C. Keystone, R. Menzies, S. Manners, E. Skamene, and R. Long Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management Lancet Infect. Dis. 3 2003 148 155
14. A. Lugering, M. Schmidt, N. Lugering, H.G. Pauels, W. Domschke, and T. Kucharzik Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway Gastroenterology 121 2001 1145 1157
15. K.L. Hyrich, A.J. Silman, K.D. Watson, and D.P. Symmons Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety Ann. Rheum. Dis. 63 2004 1538 1543
16. J. Keane, S. Gershon, R.P. Wise, E. Mirabile-Levens, J. Kasznica, and W.D. Schwieterman Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent N. Engl. J. Med. 345 2001 1098 1104
17. X. Mariette, and R. Salmon Dag French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers Ann. Rheum. Dis. 62 2003 791
18. N.R. Slifman, S.K. Gershon, J.H. Lee, E.T. Edwards, and M.M. Braun Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents Arthritis Rheum. 48 2003 319 324
19. J.H. Lee, N.R. Slifman, S.K. Gershon, E.T. Edwards, W.D. Schwieterman, and J.N. Siegel Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept Arthritis Rheum. 46 2002 2565 2570
20. F.G. De Rosa, D. Shaz, A.C. Campagna, P.E. Dellaripa, U. Khettry, and D.E. Craven Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case? Infect. Control Hosp. Epidemiol. 24 2003 477 482
21. T.L. Tai, K.P. O'Rourke, M. McWeeney, C.M. Burke, K. Sheehan, and M. Barry Pneumocystis carinii pneumonia following a second infusion of infliximab Rheumatology (Oxford) 41 2002 951 952
22. G. Haerter, B.J. Manfras, Y. de Jong-Hesse, H. Wilts, T. Mertens, and P. Kern Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis Clin. Infect. Dis. 39 2004 e88 e94
23. K. Clodi, D. Wimmer, Y. Li, R. Goodwin, U. Jaeger, and G. Mann Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells Br. J. Haematol. 111 2000 580 586
24. S.M. Lens, K. Tesselaar, B.F. den Drijver, M.H. van Oers, and R.A. van Lier A dual role for both CD40-ligand and TNF-alpha in controlling human B cell death J. Immunol. 156 1996 507 514
25. J. Askling, M. Fored, E. Baecklund, L. Brandt, C. Backlin, and A. Ekbom Hematopoietic malignancies in rheumatoid arthritis. Lymphoma risk and characteristics following TNF-antagonists Ann. Rheum. Dis. 20 2005 20
26. P. Geborek, A. Bladstrom, C. Turesson, A. Gulfe, I.F. Petersson, and T. Saxne Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas Ann. Rheum. Dis. 64 2005 699 703
27. F. Wolfe, and K. Michaud Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients Arthritis Rheum. 50 2004 1740 1751
28. J.P. Franklin, D.P. Symmons, and A.J. Silman Risk of lymphoma in patients with RA treated with anti-TNF-alpha agents Ann. Rheum. Dis. 64 2005 657 658
29. K.L. Hyrich Assuming the safety of biologic therapies in rheumatoid arthritis: the challenge of study design J. Rheumatol. 32 Suppl 2005 S48 S50
30. D. Lee, and U. Bergman The quantification of drug risks in practice WHO Reg. Publ. Eur. Ser. 45 1993 79 95